STEVEN LEWIS
Immunotherapy shows promise in cancer treatment
A team of researchers, led by scientists at Yale and the biotech company Genentech, have completed a phase I clinical trial for a new cancer immunotherapy and developed biomarkers to predict its efficacy in patients. The trial’s results look promising for the potential to use personalized medicine and immunotherapies to treat cancer.
January 13, 2015